Clinical trial
Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes
NCT02668185 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes
- Lead sponsor
- Imperial College London
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 1, 2016
- Completion date
- January 1, 2017
- Enrollment
- 37 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
menopausal flushing